GSK Korea Moving Ahead To Sell Avandia With Korea's Dong-A Despite U.S. FDA Safety Study

SEOUL - Immediately following a joint U.S. FDA advisory committee vote July 14 recommending that Avandia remain on the market, GlaxoSmithKline Korea said its plan to co-market its diabetes medicine with South Korea's Dong-A Pharmaceutical will proceed as scheduled in the second half of the year